DC Circ. Upholds Exclusivity For ADHD Drug Vyvanse
A federal appeals court has ruled that the U.S. Food and Drug Administration was correct to grant five years of market exclusivity to Shire PLC's attention deficit hyperactivity disorder drug Vyvanse....To view the full article, register now.
Already a subscriber? Click here to view full article